Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/262109
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma |
Autor: | Iacoboni, Gloria; Villacampa, Guillermo; Martínez-Cibrián, Núria; Bailén, Rebeca; López-Corral, L.; Sánchez, José M.; Guerreiro, Manuel; Caballero, Ana Carolina; Mussetti, Alberto; Sancho, Juan Manuel; Hernani, Rafael; Abrisqueta, Pau; Solano, Carlos; Sureda, Anna; Briones, Javier; Martín García-Sancho, Alejandro; Kwon, Mi; Reguera-Ortega, Juan Luis; Barba, Pere | Palabras clave: | Clinical cancer research Clinical observations Hematological cancer Non- Hodgkin's lymphoma |
Fecha de publicación: | may-2021 | Editor: | John Wiley & Sons | Citación: | Cancer Medicine 10(10): 3214-3223 (2021) | Resumen: | Tisagenlecleucel (tisa-cel) is a second-generation autologous CD19-targeted chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and complete response (CR) rate in infused patients of 52% and 40%, respectively. We report outcomes with tisa-cel in the standard-of-care (SOC) setting for R/R LBCL. Data from all patients with R/R LBCL who underwent leukapheresis from December 2018 until June 2020 with the intent to receive SOC tisa-cel were retrospectively collected at 10 Spanish institutions. Toxicities were graded according to ASTCT criteria and responses were assessed as per Lugano 2014 classification. Of 91 patients who underwent leukapheresis, 75 (82%) received tisa-cel therapy. Grade 3 or higher cytokine release syndrome and neurotoxicity occurred in 5% and 1%, respectively; non-relapse mortality was 4%. Among the infused patients, best ORR and CR were 60% and 32%, respectively, with a median duration of response of 8.9 months. With a median follow-up of 14.1 months from CAR T-cell infusion, median progression-free survival and overall survival were 3 months and 10.7 months, respectively. At 12 months, patients in CR at first disease evaluation had a PFS of 87% and OS of 93%. Patients with an elevated lactate dehydrogenase showed a shorter PFS and OS on multivariate analysis. Treatment with tisa-cel for patients with relapsed/refractory LBCL in a European SOC setting showed a manageable safety profile and durable complete responses. | Descripción: | © 2021 The Authors. | Versión del editor: | http://dx.doi.org/10.1002/cam4.3881 | URI: | http://hdl.handle.net/10261/262109 | DOI: | 10.1002/cam4.3881 | E-ISSN: | 2045-7634 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Real-world evidence_Iacoboni_PV_Art2021.pdf | 655,62 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
34
checked on 10-abr-2024
SCOPUSTM
Citations
68
checked on 24-abr-2024
WEB OF SCIENCETM
Citations
64
checked on 21-feb-2024
Page view(s)
74
checked on 29-abr-2024
Download(s)
76
checked on 29-abr-2024